Literature DB >> 11727721

Principles of pharmaceutical management of spastic hypertonia.

E Elovic1.   

Abstract

Spasticity and hypertonicity are common components of the upper motor neuron syndrome (UMNS), which is seen in various neurologic conditions. Pharmacologic agents that can be administered through different routes can play an important part in treatment aimed at minimizing complications, pain, and functional deficits caused by UMNS. They can be administered by way of an oral, transdermal, intramuscular, or intrathecal route and can play an important role in the management of UMNS. This article reviews UMNS, the functional consequences that can result from it, individual agents, and their indications, complications, and adverse effects. Algorithms for treatment of UMNS with pharmacologic agents, and these agents' efficacy in different neurologic populations, is reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11727721

Source DB:  PubMed          Journal:  Phys Med Rehabil Clin N Am        ISSN: 1047-9651            Impact factor:   1.784


  7 in total

Review 1.  Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury.

Authors:  Alexander G Rabchevsky; Patrick H Kitzman
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 2.  Chemodenervation for treatment of limb spasticity following spinal cord injury: a systematic review.

Authors:  J Lui; M Sarai; P B Mills
Journal:  Spinal Cord       Date:  2015-01-13       Impact factor: 2.772

3.  Preconditioning with Gua Lou Gui Zhi decoction enhances H2O2-induced Nrf2/HO-1 activation in PC12 cells.

Authors:  Jingjie Mao; Zuanfang Li; Ruhui Lin; Xiaoqin Zhu; Jiumao Lin; Jun Peng; Lidian Chen
Journal:  Exp Ther Med       Date:  2015-07-01       Impact factor: 2.447

4.  Identifying and classifying quality of life tools for assessing spasticity after spinal cord injury.

Authors:  Christina Balioussis; Sander L Hitzig; Heather Flett; Luc Noreau; B Catharine Craven
Journal:  Top Spinal Cord Inj Rehabil       Date:  2014

Review 5.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  Enhancing KCC2 activity decreases hyperreflexia and spasticity after chronic spinal cord injury.

Authors:  Jadwiga N Bilchak; Kyle Yeakle; Guillaume Caron; Dillon Malloy; Marie-Pascale Côté
Journal:  Exp Neurol       Date:  2021-01-13       Impact factor: 5.330

Review 7.  Baclofen in the Therapeutic of Sequele of Traumatic Brain Injury: Spasticity.

Authors:  Adán Pérez-Arredondo; Eduardo Cázares-Ramírez; Paul Carrillo-Mora; Marina Martínez-Vargas; Noemí Cárdenas-Rodríguez; Elvia Coballase-Urrutia; Radamés Alemón-Medina; Aristides Sampieri; Luz Navarro; Liliana Carmona-Aparicio
Journal:  Clin Neuropharmacol       Date:  2016 Nov/Dec       Impact factor: 1.592

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.